CAR T therapy for ovarian cancer that no longer responds to platinum
Treatments studied
Part of Cancer, Immune system & allergy, Women’s health & pregnancy clinical trials.
This Phase 1 study tests a one-time treatment made from your immune cells (CAR T) to attack a protein found on some ovarian cancer cells. It is for people whose ovarian cancer has come back or worsened after platinum chemotherapy, aiming to see safety and early signs of benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and willing to sign consent
- You have platinum-resistant epithelial ovarian cancer (it worsened within 6 months of platinum, or while on the latest platinum treatment)
- Your tumor must test positive for TAG72 protein in lab testing (enough cells with strong staining)
- You have tried other cancer medicines besides platinum (like taxanes and/or other options) and either it did not work or you could not tolerate them
- Your body can handle treatment: adequate blood counts and organ function (kidney, liver, and heart function above set limits)
- You cannot have certain conditions, like active autoimmune disease needing strong medicines, active infections like hepatitis or HIV, or prior serious lung inflammation/pneumonitis requiring steroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy (CAR T-cells) for people with advanced pancreatic cancer, sarcoma, or breast cancer that has not responded to standard treatments. It may be an option if you have tried other therapies and are looking for a new approach.
This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.
This study tests an experimental therapy called SCT-001 CAR T cells, made from your own immune cells, for ovarian cancer that has not responded to standard treatments. The goal is to see if these engineered cells can find and attack your cancer cells, which could help shrink or control the disease.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
Hear when a new Platinum-Resistant Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.